Rubicon Research IPO

Rubicon Research IPO is listed on BSE and NSE, priced at ₹461–₹485 per share. The stock debuted at ₹620, delivering a listing gain of 27.8%. The IPO had a lot size of ₹30 shares and a minimum investment of ₹14,550.

Rubicon Research Limited IPO

Mainboard Listed
₹14,550 (30 Shares)
Minimum Investment
Check Allotment
IPO Dates
Oct 9, 2025 – Oct 13, 2025
Price band
₹461-485 per equity share
Minimum Investment
₹14,550
Issue size
₹1377.5 Cr
Lot size
30
Allotment Date
Oct 14, 2025
Listing
Oct 16, 2025
Listing At
BSE, NSE

IPO timeline

  1. Oct 9, 2025

    Open Date

    Completed

  2. Oct 13, 2025

    Close Date

    Completed

  3. Oct 14, 2025

    Allotment Date

    Completed

  4. Oct 16, 2025

    Listing Date

    Completed

Price Summary

Last closing
960.05 (97.95%)
52 week high
1,013.40
52 week low
570.75
Last update

Rubicon Research IPO Subscription Details

View Subscription Details
QIB 137.09x
Retail 37.33x
NIIs 102.71x
bHNI 117.77x
sHNI 72.57x
Retail 37.33x
EMP 17.69x
Total 109.33x

Rubicon Research IPO subscription status shows demand across QIB, NII, and retail categories, helping investors understand participation levels.

Last updated:

Rubicon Research IPO Essentials

Rubicon Research IPO Details

Rubicon Research IPO is priced at ₹461-485 per share with a total issue size of 1377.5 crore. The IPO has a lot size of 30 shares and is listed on BSE and NSE.

Issue price
₹461-485 per equity share
Lot size
30 shares
Face value
₹1 Per Equity Share
Issue size
Total 1,377.50 Cr :
#Fresh Issue : 1,03,09,278 shares(aggregating up to ₹500.00 Cr) +
#OFS : 1,80,92,762 shares of ₹1(aggregating up to ₹877.50 Cr)
Total issue size
2,84,02,040 shares
(aggregating up to ₹1377.5 crore)
Fresh issue
1,03,09,278 shares
(aggregating up to ₹500 crore)
Offer for sale (OFS)
1,80,92,762 shares
(aggregating up to ₹877.5 crore)
Listing at
BSE, NSE
List price
620.0(NSE)
Listing date
Registrar
Axis Capital Ltd
IIFL Capital Services Ltd
JM Financial Ltd
SBI Capital Markets Ltd
Lead manager
MUFG Intime India Pvt.Ltd.

Market Lot Size

Investors can bid for a minimum of 30 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.

Application Lots Shares Amount
Retail (min) 1 30 ₹14,550
Retail(max) 13 390 ₹1,89,150
sHNI(min) 14 420 ₹2,03,700
sHNI(max) 68 2,040 ₹9,89,400
sHNI(min) 69 2,070 ₹10,03,950

Rubicon Research IPO Documents

Rubicon Research IPO Reservation

Rubicon Research IPO reservation details show category-wise allocation of shares. Out of the total 2,84,02,042 shares, approximately 29.95% are reserved for QIB, 14.98% for NII, 9.99% for retail investors, 0.14% for employees, and 44.94% for anchor investors.

Investor Category Shares Offered Maximum Allottees
Anchor Investor Shares Offered 1,27,64,691 (44.94%)
QIB Shares Offered 85,06,804 (29.95%)
NII (HNI) Shares Offered 42,54,299 (14.98%)
bHNI > ₹10L 28,36,200 (9.99%) 6754
sHNI < ₹10L 14,18,099 (NA%) 3377
Retail Shares Offered 2,83,62,00 (9.99%) 94553
Employee Shares Offered 40,046 (0.14%)
Total Shares Offered 2,84,02,042 (100%)

Rubicon Research IPO Analytics

Rubicon Research IPO category-wise subscription trends show day-wise participation across QIB, NII, and retail investors.

Rubicon Research IPO Subscription Status

Rubicon Research IPO subscription status shows demand across retail, NII, and QIB categories, helping investors understand overall participation trends.

The IPO is currently subscribed 109.33x, indicating strong demand across investor categories.

As on QIB
NII
bHNI
sHNI
Retail Total
Shares Offered / Reserved 85,06,804
42,54,299
28,36,200
14,18,100
28,36,200 1,56,37,349
Day 1 09-10-25 05:00 PM
0.27 x
0.49x
0.40x
0.68x
1.47 x 0.55 x
Day 2 10-10-25 05:00 PM
2.22 x
1.93x
1.60x
2.58x
4.19 x 2.50 x
Day 3 13-10-25 05:00 PM
137.09 x
102.70x
117.77x
72.57x
37.33 x 109.33 x
Total No. of Applications
bHNI sHNI Retail
3227763 (Approx) 23.02x 69.33x 29.54x

Rubicon Research Valuations

Earnings

EPS Pre IPO
₹8.70/-
EPS Post IPO
₹10.51/-
P/E Pre IPO
55.75
P/E Post IPO
46.13

Returns

ROE
29.02%
ROCE
26.45%
RoNW
29.02%
PAT Margin
10.37%

Fundamentals

Debt / Equity
0.73
Market Cap
7990.21 Cr.

Data sourced from DRHP / RHP • For educational purposes only

Rubicon Research Financials( In Crs.)

30-Jun-25 31-Mar-25 31-Mar-24 31-Mar-23
Assets 1647.60 1451.43 1109.49 749.70
Revenue 356.95 1296.22 872.39 419.00
Profit After Tax 43.30 134.36 91.01 -16.89
Net Worth 593.67 540.98 385.00 286.38
Reserves & Surplus 397.50 525.57 369.79 281.31
Total Borrowing 495.78 393.17 396.41 317.91

Rubicon Research Company & Offer Insights

About Rubicon Research

Founded in 1999, Rubicon Research Limited is a pharmaceutical organization that deals with the development, manufacturing, and marketing of differentiated formulation.

As of March 31, 2024, Rubicon Research Limited had an approved portfolio of 69 active Abbreviated New Drug Application (ANDA) and New Drug Application (NDA) products of the US FDA. The portfolio comprises 55 commercialized products of which the US generic pharmaceutical market size is USD 2,386.6 million and which has contributed USD 154.3 million by Rubicon Research Limited during Fiscal 2024.

Rubicon Research Promoter(s)

General Atlantic Singapore RR Pte. Ltd., Pratibha Pilgaonkar, Sudhir Dhirendra Pilgaonkar, Parag Suganchand Sancheti, Surabhi Parag Sancheti and Sumant Sudhir Pilgaonkar are the company's promoters of Rubicon Research.

Rubicon Research IPO Issue Objectives

Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by the Company
Funding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes

Rubicon Research IPO - Anchor Investors

Rubicon Research raises Rs 619 crore from 32 anchor investors prior to Rs 1,377 crore IPO.
International marquee investors such as Goldman Sachs, Fidelity, Nomura Funds, Amansa Holdings, Societe Generale, University of Notre Dame, and GP Emerging Markets Strategies.
Rubicon Research in its exchange filing on Wednesday reported that it has completed allotment of 1,27,64,691 equity shares to anchor investors at Rs 485 per share.
Out of this, 49.56 lakh shares (38.83 percent of the anchor allotment) valued at Rs 240.4 crore went to eight domestic mutual funds such as PGIM India, Mirae Asset, Bajaj Finserv, Kotak Mahindra AMC, HDFC AMC, and ICICI Prudential Mutual Fund.

Rubicon Research IPO - Peers Comparison

P/B Ratio P/E Ratio RoNW Revenue(in Cr.)
Rubicon Research N/A N/A 29.02% 1284
Sun Pharma 5.31 34.9 16.1% 52578
Aurobindo Pharma 1.93 18.1 11.1% 31723
Zydus Lifesciences 4.1 21.8 21.3% 23241
Strides Pharma 2.9 18.2 17.2% 4564
Dr. Reddy’s Lab 3.0 18.05 18.5% 32643
Alembic Pharma 3.4 30.4 11.6% 6672
Lupin 5.0 26.6 21.0% 22709

Rubicon Research IPO - Strengths and Risks

Rubicon Research IPO strengths and risks highlight key business factors, financial position, and market sentiment that may impact investor interest.

Strengths

Has a strong portfolio of products commercialised, with a market share of more than 25% in seven products in the US market.
R&D capacities at India and Canada facilitate product development and innovation, less dependent on third parties.
Built US sales and distribution platform through subsidiaries to cover both branded and non-branded product markets.
Reveals regulatory compliance with US FDA checks and approvals from international agencies.

Risks

The firm is strongly dependent on the US market and thus is exposed to negative developments there.
Being in a highly regulated sector, product recalls, inspection failure, or closure of plants would have a detrimental effect on operations.
A high success rate of R&D activities translating into marketable products is not always guaranteed, exposing revenue growth to risks.
Severe competition in the drug industry could impact margins and hamper future growth opportunities.

Contact Information

Contact Details

Rubicon Research

022 61414000

investors@rubicon.co.in

https://www.rubicon.co.in/

MedOne House, B-75, Road No. 33, Wagle Estate, Thane West-400604, Maharashtra, India Thane, Maharashtra, 400604

Registrar Contact Details

MUFG Intime India Private Limited (Link Intime)

+91-22-4918 6270

rubicon.ipo@linkintime.co.in

https://in.mpms.mufg.com/Initial_Offer/public-issues.html

Frequently Asked Questions

Click any question to reveal the answer

Rubicon Research IPO is a book-built IPO worth ₹1377.5 crore. The price band is ₹461–₹485 per share. The IPO opens on Oct 9, 2025 and closes on Oct 13, 2025. It will be listed on BSE and NSE. Axis Capital Ltd IIFL Capital Services Ltd JM Financial Ltd SBI Capital Markets Ltd is the registrar.

The price band of Rubicon Research IPO is ₹461 to ₹485 per share.

The lot size of Rubicon Research IPO is 30 shares.

The minimum investment for Rubicon Research IPO is approximately ₹14,550 based on the upper price band .

Rubicon Research IPO opens on Oct 9, 2025 and closes on Oct 13, 2025.

The allotment date of Rubicon Research IPO is Oct 14, 2025.

Rubicon Research IPO is expected to be listed on Oct 16, 2025, on BSE and NSE .

Rubicon Research IPO listed on Oct 16, 2025. It was issued at ₹620.0(NSE) and is currently around ₹960.05 as on 14-May-2026 3:30 PM, which is approximately 97.9% versus issue price. The 52-week high is ₹1,013.40.

Based on listing and post-listing performance, Rubicon Research IPO delivered around 97.9% over issue price. Whether it was worth applying depends on your risk profile, allocation, and holding horizon.

To buy Rubicon Research IPO shares after listing, log in to your broker app (such as Zerodha, Angel One, Groww, Upstox, ICICI Direct), search the stock symbol, place a delivery/CNC order, and confirm quantity and price.

Rubicon Research IPO valuation snapshot: P/E 46.13, EPS ₹10.51/-, P/B N/A, RoNW 29.02%, and market cap 7990.21 Cr.

To apply for Rubicon Research IPO, open the IPO Ji app or website, select the IPO, choose your demat account, enter the quantity, and submit the application.

You can check the live subscription status of Rubicon Research IPO on IPO Ji or stock exchange websites. It shows real-time demand across retail, NII, and QIB categories.

Pre-apply allows investors to submit their IPO application before the bidding period starts. The order is placed automatically when the IPO opens.

If you pre-apply for Rubicon Research IPO, your order will be placed when the IPO bidding starts, and a UPI mandate request will be generated.

You can check Rubicon Research IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Rubicon Research IPO allotment status on IPO Ji for quick and easy access.